As­traZeneca’s Imfinzi/treme­li­mum­ab com­bo fiz­zles again on lung can­cer

As­traZeneca has found an­oth­er trap door for its com­bi­na­tion of the PD-L1 check­point Imfinzi and its CT­LA-4 com­bi­na­tion drug treme­li­mum­ab.

The re­search team on ARC­TIC …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER